NCT03681158View on ClinicalTrials.gov

Study of Excretion Balance and Pharmacokinetics of [14C]-Sodium Valproate (3.7 MBq) in Healthy Postmenopausal or Permanently Sterile Female Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

October 5, 2018

Primary Completion Date

April 11, 2019

Study Completion Date

April 11, 2019

Conditions
Epilepsy
Interventions
DRUG

sodium valproate

Pharmaceutical form:Powder for oral solution reconstituted with water Route of administration: Oral

Trial Locations (1)

Unknown

Investigational site number, Nottingham

Sponsors

Lead Sponsor

Sanofi
All Listed Sponsors
lead

Sanofi

INDUSTRY